Sign In
Buy HALO
$82.54
-0.760 (-0.91%)
At Close: Jul 31, 2026
Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares of Stock
04:48am, Friday, 03'rd Apr 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the company's stock in a transaction dated Thursday, April 2nd. The shares were sold at an average p
Congress Asset Management Co. Cuts Position in Halozyme Therapeutics, Inc. $HALO
02:42pm, Tuesday, 24'th Mar 2026
Congress Asset Management Co. decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 9.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange C
13,475 Shares in Halozyme Therapeutics, Inc. $HALO Purchased by CWA Asset Management Group LLC
01:50pm, Tuesday, 24'th Mar 2026
CWA Asset Management Group LLC acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ: HALO) in the undefined quarter, according to the company in its most recent Form 13F filing with the Secu
Why Is Halozyme Therapeutics (HALO) Down 13.1% Since Last Earnings Report?
12:31pm, Thursday, 19'th Mar 2026
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
HALO Helps, But Dividend Investors Still Need to Be Selective
12:28pm, Wednesday, 18'th Mar 2026
The latest buzz acronym in the investment community, spurred in part by the artificial intelligence (AI) trade, is HALO, or “heavy assets, low obsolescence.” The catchy acronym is relevant to divi
Alliancebernstein L.P. Trims Stake in Halozyme Therapeutics, Inc. $HALO
03:46am, Tuesday, 17'th Mar 2026
Alliancebernstein L.P. reduced its holdings in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 22.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Co
Aquatic Capital Management LLC Acquires Shares of 89,651 Halozyme Therapeutics, Inc. $HALO
03:25am, Monday, 16'th Mar 2026
Aquatic Capital Management LLC bought a new position in Halozyme Therapeutics, Inc. (NASDAQ: HALO) during the third quarter, according to its most recent 13F filing with the SEC. The fund bought 89,65
Halozyme Therapeutics, Inc. $HALO Shares Bought by ArrowMark Colorado Holdings LLC
03:50am, Sunday, 15'th Mar 2026
ArrowMark Colorado Holdings LLC grew its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 6.7% during the third quarter, according to the company in its most recent Form 13F filing
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of “Hold” by Brokerages
02:44am, Saturday, 14'th Mar 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) has earned an average rating of "Hold" from the twelve ratings firms that are currently covering the company, MarketBeat.com reports. One i
Halozyme Appoints David Ramsay as Interim Chief Financial Officer
08:30am, Thursday, 12'th Mar 2026
SAN DIEGO, March 12, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced that David Ramsay has been appointed Interim Chief Financial Officer
Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript
01:22pm, Wednesday, 11'th Mar 2026
Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript
Fieldview Capital Management LLC Makes New $785,000 Investment in Halozyme Therapeutics, Inc. $HALO
04:21am, Wednesday, 11'th Mar 2026
Fieldview Capital Management LLC purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) during the undefined quarter, according to the company in its most recent 13F filing w
Halozyme Therapeutics, Inc. (HALO) Presents at Leerink Global Healthcare Conference 2026 Transcript
03:00pm, Tuesday, 10'th Mar 2026
Halozyme Therapeutics, Inc. (HALO) Presents at Leerink Global Healthcare Conference 2026 Transcript
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma
08:00am, Friday, 06'th Mar 2026
FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression ‑free survival and overall survival versus standard of care regimens SAN DIEGO, March 6, 2026 /
NovelStem International (OTCMKTS:NSTM) and Halozyme Therapeutics (NASDAQ:HALO) Head to Head Contrast
02:24am, Friday, 06'th Mar 2026
NovelStem International (OTCMKTS:NSTM - Get Free Report) and Halozyme Therapeutics (NASDAQ: HALO - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the tw
